Suppr超能文献

[抗心律失常药物的失效与对致心律失常现象的理解]

[Failure of antiarrhythmia agents and understanding the phenomenon of proarrhythmia].

作者信息

Semrád B

机构信息

Interní kardiologická klinika Lékarské fakulty MU a FN Brno, pracovistĕ Bohunice.

出版信息

Vnitr Lek. 2003 Sep;49(9):700-6.

Abstract

The end of 80ies and the beginning of 90ies in arrhythmology was characterized by the demonstration of so called proarrhythmia, when drugs, particularly antiarrhythmic ones, induced serious, frequently fatal arrhythmias. The resulting pharmacotherapeutic skepsis in the treatment of, in particular, ventricular arrhythmias were accompanied at the same time by a powerful development of non-pharmacological modes of treatment of arrhythmias, especially by implantable defibrillators. The causes of proarrhythmia were identified with the evolution of knowledge in the genetic basis of hereditary syndrome of long QT interval. The first mutation was identified in 1991 and other mutations in the four subsequent years. The mutated genes controlling the synthesis of ionic membrane channels cause disorders in the repolarization phase of action potential. Their expression in individual types of myocytes is not homogenous, most affected being the M cells of ventricular myocardium. It results in a dispersion of repolarization which, together with induction of early after depolarization, causes the origin of polymorphic ventricular tachycardia--TdP. In the 90ies of 20th century there were increasingly frequent reports on sudden arrhythmic death in patients, who had been treated with non-cardiac drugs. They were caused by polymorphic ventricular tachycardia associated with the long QT interval. The syndrome was named as acquired syndrome of long QT interval, based on the drug-induced delayed repolarization of myocyte. The slowing-down is caused by affected membrane channels known from the syndrome of hereditary LQTS. The very low frequency of these fatal complications has been explained either by an obscure genetic defect or a disorder in metabolism of the therapeutic drug, but especially due to drug interactions metabolized in a similar way and similarly influencing the function of membrane channels. Sixty drug molecules with proarrhythmic potential have been identified so far, but the list is probably not complete yet.

摘要

心律失常学领域在20世纪80年代末和90年代初的特点是出现了所谓的致心律失常作用,即药物,尤其是抗心律失常药物,诱发严重的、常常致命的心律失常。由此产生的对药物治疗,尤其是室性心律失常治疗的怀疑,与此同时伴随着心律失常非药物治疗方式的蓬勃发展,特别是植入式除颤器的发展。随着对长QT间期遗传性综合征遗传基础认识的发展,致心律失常作用的原因得以明确。1991年发现了第一个突变,随后四年又发现了其他突变。控制离子膜通道合成的突变基因导致动作电位复极化阶段出现紊乱。它们在不同类型心肌细胞中的表达并不均匀,受影响最大的是心室肌的M细胞。这导致复极化离散,再加上早期后除极的诱导,引发多形性室性心动过速——TdP。在20世纪90年代,越来越多关于接受非心脏药物治疗的患者发生心律失常性猝死的报道出现。这些猝死是由与长QT间期相关的多形性室性心动过速引起的。基于药物诱导的心肌细胞复极化延迟,该综合征被命名为获得性长QT间期综合征。这种减慢是由遗传性LQTS综合征中已知的受影响膜通道引起的。这些致命并发症的发生率极低,其原因要么是不明的基因缺陷,要么是治疗药物代谢紊乱,但尤其是由于以相似方式代谢且同样影响膜通道功能的药物相互作用。到目前为止,已确定有60种具有致心律失常潜力的药物分子,但这份清单可能还不完整。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验